Ciprobay 750 mg (Ciprofloxacin HCl): Clinical Monograph, Dosing & Safety

CIPROBAY® 750 mg Film-Coated Tablets (Ciprofloxacin Hydrochloride)

1. Disclaimer

This clinical monograph is intended solely for educational, scientific, and informational purposes by healthcare professionals, pharmacists, and medical researchers. It does not constitute individual medical advice, diagnosis, or treatment recommendations. Prescribers and healthcare practitioners must exercise independent clinical judgment and consult official local prescribing information, institutional antimicrobial stewardship guidelines, and regulatory agency updates prior to initiating or modifying therapy.

We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.

2. Summary

Ciprobay® 750 mg is a high-potency, broad-spectrum oral fluoroquinolone antibacterial formulation containing ciprofloxacin hydrochloride monohydrate. It exerts concentration-dependent, bactericidal activity by selectively inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), preventing bacterial chromosomal supercoiling, DNA replication, and repair.

The 750 mg strength is indicated primarily for deep-seated, severe, or high-bacterial-load systemic infections caused by susceptible Gram-negative pathogens (including Pseudomonas aeruginosa and members of Enterobacterales) and specific Gram-positive and atypical organisms. Key indications include severe lower respiratory tract infections (bronchopulmonary infections in cystic fibrosis or bronchiectasis), complicated bone and joint infections (osteomyelitis, septic arthritis), malignant external otitis, severe intra-abdominal infections (in combination with antianaerobic coverage), complicated urinary tract infections, and post-exposure prophylaxis or treatment of inhalational anthrax.

In alignment with major international health authorities — the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA) — systemic fluoroquinolones, including ciprofloxacin, carry boxed / class-wide safety warnings because of the risk of disabling, long-lasting, and potentially irreversible multi-system toxicities (tendinitis, tendon rupture, peripheral neuropathy, and central nervous system disorders). Following the EMA's 2018–2019 EU-wide referral, a 2023 EMA Direct Healthcare Professional Communication, and the MHRA Drug Safety Update of January 2024, systemic fluoroquinolones must only be prescribed when other commonly recommended antibiotics are inappropriate, and must not be used for mild, self-limiting, or uncomplicated infections unless alternative antimicrobial agents cannot be utilized.

3. Brand Name

Ciprobay® (also distributed under trade names such as Cipro®, Ciproxin®, and Ciprobay® HC in select jurisdictions).

4. Category

• Pharmacological Class: Synthetic Broad-Spectrum Fluoroquinolone Antibacterial.
• Therapeutic Class: Systemic Antibiotic / Gyrase Inhibitor.
• ATC Classification: J01MA02 (Antibacterials for systemic use, fluoroquinolones).
• WHO AWaRe Classification: "Watch" group antibiotic (higher resistance potential; priority target of antimicrobial stewardship programmes).

5. Active Ingredient

• Chemical Entity: Ciprofloxacin (as ciprofloxacin hydrochloride monohydrate).
• Chemical Name: 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid hydrochloride monohydrate.
• Molecular Formula: C17H18FN3O3 · HCl · H2O
• Molecular Weight: 385.8 g/mol (hydrochloride monohydrate); 331.34 g/mol (free base).
• CAS Registry Number: 86393-32-0 (monohydrate); 85721-33-1 (free base).

6. Pharmaceutical Form & Strength

• Dosage Form: Film-coated tablet for oral administration.
• Strength: Each tablet contains 750 mg of ciprofloxacin (equivalent to 873 mg ciprofloxacin hydrochloride monohydrate).
• Visual Appearance: Oblong, nearly white to slightly yellowish, biconvex film-coated tablet, debossed with “CIP 750” on one face and the "BAYER" cross logo on the reverse face.
• Presentation (Egyptian market): Carton box of 10 film-coated tablets.

7. Manufacturer & Marketing Authorization Holder

• Manufacturer / Local Manufacturing Site: Hikma Pharma S.A.E., 2nd Industrial Zone, 6th of October City, Giza, Egypt.
• Licensor / Marketing Authorization Holder (MAH): Bayer AG / Bayer Schering Pharma AG, Leverkusen/Berlin, Germany.
• Distribution & Quality Oversight: Manufactured under strict current Good Manufacturing Practice (cGMP) standards in accordance with licensed Bayer technical specifications and Hikma Quality Management Systems.

8. Mechanism of Action

Ciprofloxacin exerts bactericidal activity via inhibition of essential bacterial type II topoisomerases:

1. DNA Gyrase (Topoisomerase II): Composed of GyrA and GyrB subunits; it introduces negative supercoils into double-stranded DNA to relieve topological strain ahead of replication forks. Ciprofloxacin stabilizes the enzyme-DNA cleavage complex, stalling replication forks and triggering double-stranded chromosomal breaks.
2. Topoisomerase IV: Composed of ParC and ParE subunits; it mediates the decatenation (unlinking) of daughter chromosomal DNA rings following replication. Inhibition by ciprofloxacin prevents segregation of replicated daughter chromosomes into new daughter cells.

In Gram-negative organisms, DNA gyrase is the primary target, whereas in Gram-positive organisms, topoisomerase IV is predominantly targeted.

• Pharmacodynamic Indices: Ciprofloxacin demonstrates concentration-dependent bacterial killing. The major pharmacokinetic/pharmacodynamic (PK/PD) surrogate correlates of clinical and bacteriological efficacy are:
  • Ratio of 24-hour Area Under the Curve to Minimum Inhibitory Concentration (AUC24/MIC). For Gram-negative pathogens (e.g., P. aeruginosa, Enterobacterales), an AUC24/MIC ≥ 125 is associated with optimal clinical cure and suppression of resistance.
  • Ratio of Peak Serum Concentration to Minimum Inhibitory Concentration (Cmax/MIC ≥ 10:1).

9. Spectrum of Activity

Ciprofloxacin has a broad spectrum of in vitro activity, predominantly skewed toward aerobic Gram-negative bacilli:

Susceptible Organisms (when local susceptibility is confirmed)

• Aerobic Gram-Negative Microorganisms:
  • Enterobacterales: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, Providencia spp.
  • Non-Fermentative Gram-Negative Bacilli: Pseudomonas aeruginosa (activity is dose-dependent; higher doses [750 mg q12h] required), Moraxella catarrhalis, Acinetobacter baumannii (variable).
  • Fastidious Gram-Negative Bacilli: Haemophilus influenzae, Haemophilus parainfluenzae, Legionella pneumophila, Campylobacter jejuni, Pasteurella multocida, Brucella spp., Francisella tularensis, Yersinia pestis, Vibrio cholerae.
  • Enteric Pathogens: Salmonella enterica (including Salmonella enterica serovar Typhi), Shigella spp.
• Aerobic Gram-Positive Microorganisms:
  • Bacillus anthracis (highly susceptible; utilized for prophylaxis and therapy).
  • Staphylococcus aureus (methicillin-susceptible isolates [MSSA]; however, resistance emerges rapidly on monotherapy).
  • Staphylococcus epidermidis (coagulase-negative staphylococci).
• Atypical Pathogens:
  • Chlamydia trachomatis, Chlamydophila pneumoniae, Mycoplasma pneumoniae.

Inherently Resistant or Commonly Problematic Organisms

• Gram-Positive: Streptococcus pneumoniae (intrinsically suboptimal susceptibility; ciprofloxacin should not be used as empirical monotherapy for pneumococcal pneumonia), Enterococcus faecalis (frequently resistant/intermediate), Enterococcus faecium (intrinsically resistant), Methicillin-resistant Staphylococcus aureus (MRSA; nearly universally co-resistant to fluoroquinolones).
• Strict Anaerobes: Bacteroides fragilis, Clostridioides difficile, Fusobacterium spp., Prevotella spp., and Peptostreptococcus spp. exhibit limited susceptibility. Ciprofloxacin monotherapy is inappropriate in mixed anaerobic-aerobic infections (e.g., intra-abdominal or pelvic abscesses) without concurrent anaerobic agents (such as metronidazole).
• Other Non-Susceptible Species: Stenotrophomonas maltophilia, Burkholderia cepacia, Actinomyces spp., Listeria monocytogenes, Nocardia asteroides, Ureaplasma urealyticum.

Resistance Mechanisms

• Chromosomal Mutations: Stepwise alterations in the Quinolone Resistance-Determining Regions (QRDR) of target genes: gyrA / gyrB (DNA gyrase) and parC / parE (topoisomerase IV). Single-point mutations confer low-level resistance; cumulative mutations confer high-level, class-wide resistance.
• Active Efflux & Impermeability: Overexpression of multi-drug resistance (MDR) efflux pumps (e.g., MexAB-OprM in P. aeruginosa, AcrAB-TolC in E. coli) and down-regulation of outer membrane porins (e.g., OprD, OmpF).
• Plasmid-Mediated Quinolone Resistance (PMQR): Mediated by qnr genes (pentapeptide proteins protecting DNA gyrase from fluoroquinolones), aac(6')-Ib-cr (an aminoglycoside acetyltransferase variant that acetylates ciprofloxacin), and plasmid-encoded efflux pumps (qepA, oqxAB).

10. Pharmacokinetics

Absorption

• Bioavailability: Rapidly and extensively absorbed primarily from the proximal small intestine; absolute oral bioavailability is approximately 70% to 80%.
• Peak Plasma Concentration (Cmax): Oral administration of a single 750 mg film-coated tablet generates a mean peak serum concentration of 3.0 to 3.7 mg/L within 1.0 to 2.0 hours (Tmax) under fasting conditions.
• Food Effects: Co-administration with meals high in calories causes a minor delay in absorption (Tmax shifts), but total extent of absorption (AUC) is not clinically altered. However, concurrent ingestion with isolated dairy products or mineral-fortified juices (rich in multivalent cations) substantially impairs bioavailability via insoluble chelate formation.

Distribution

• Plasma Protein Binding: Low (20% to 30%), leaving the free, pharmacologically active drug available for tissue penetration.
• Volume of Distribution (Vd): High steady-state volume of distribution ranging between 2.0 and 3.0 L/kg, indicating extensive extravascular penetration.
• Tissue Penetration: Concentrations in target tissues frequently match or exceed concurrent serum levels:
  • Respiratory System: High concentrations in pulmonary epithelial lining fluid (ELF), alveolar macrophages, and bronchial mucosa.
  • Genitourinary Tract: Substantial concentrations in renal parenchyma, bladder wall, prostatic fluid/tissue, and urine (exceeding serum concentrations by 10- to 100-fold).
  • Biliary & Abdominal: Concentrates heavily in bile, gallbladder tissue, and peritoneal fluid.
  • Skeletal System: Penetrates cortical and cancellous bone, cartilage, and synovial fluid, achieving therapeutic levels needed for osteomyelitis.
  • Central Nervous System: Modest cerebrospinal fluid (CSF) penetration; concentrations in uninflamed meninges are about 10% of serum levels, rising to 30–40% in the presence of inflamed meninges.

Biotransformation (Metabolism)

• Approximately 10% to 15% of the absorbed dose undergoes hepatic biotransformation via low-affinity pathways.
• Four minor metabolites with reduced antimicrobial activity have been identified:
  • Desethyleneciprofloxacin (M1, 1–2%)
  • Sulphociprofloxacin (M2, 1–3%)
  • Oxociprofloxacin (M3, 4–6%)
  • Formylciprofloxacin (M4, < 0.1%)
• Enzymatic Inhibition: Ciprofloxacin is a potent, mechanism-based moderate-to-strong inhibitor of cytochrome P450 isoenzyme CYP1A2.

Elimination & Excretion

• Renal Clearance: Primary route of elimination. Renal clearance is approximately 180 to 300 mL/kg/h (3 to 5 mL/min/kg), mediated both by glomerular filtration and active carrier-mediated tubular secretion (via organic cation/anion transporters).
• Urinary Excretion: Approximately 40% to 50% of an oral dose is excreted unchanged in the urine within 24 hours. Urinary concentrations typically exceed 200 mg/L during the first 2 hours post-dose and remain > 30 mg/L at 12 hours.
• Non-Renal Elimination: Approximately 20% to 35% is excreted in feces, reflecting both unabsorbed drug, active trans-intestinal secretion across the intestinal mucosa, and biliary excretion (1–2% of the dose).
• Elimination Half-Life (t½): Approximately 4.0 to 7.0 hours in individuals with normal renal function. In end-stage renal disease (ESRD), the elimination half-life is prolonged, with values up to approximately 8–12 hours reported.

11. Indications

Due to the risk of severe adverse reactions and the rising prevalence of antimicrobial resistance, Ciprobay® 750 mg is reserved primarily for serious or complicated bacterial infections documented or strongly suspected to be caused by susceptible organisms:

1. Severe Lower Respiratory Tract Infections

• Severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) caused by Gram-negative pathogens when other options fail or are contraindicated.
• Bronchopulmonary infections in cystic fibrosis or bronchiectasis associated with Pseudomonas aeruginosa.
• Hospital-acquired (nosocomial) pneumonia or community-acquired pneumonia with documented Gram-negative/pseudomonal etiology (in combination with other antipseudomonal agents; not indicated as monotherapy for pneumococcal community-acquired pneumonia).

2. Complicated Ear, Nose, & Throat Infections

• Malignant (necrotizing) external otitis (requires prolonged therapy with 750 mg twice daily).
• Chronic suppurative otitis media refractory to initial therapies.
• Severe acute exacerbation of chronic sinusitis, restricted to instances where first-line beta-lactam therapies have failed or cannot be prescribed.

3. Complicated Urogenital & Renal Infections

• Complicated pyelonephritis (especially with structural or functional urinary tract abnormalities).
• Complicated urinary tract infections (cUTI), recurrent catheter-associated UTI.
• Acute and chronic bacterial prostatitis (ciprofloxacin penetrates deeply into prostatic stroma and secretions).

4. Complicated Bone & Joint Infections

• Chronic osteomyelitis and septic arthritis caused by susceptible Gram-negative organisms (such as P. aeruginosa, Enterobacterales), requiring high tissue exposure over prolonged periods (up to 3 months).

5. Severe Intra-Abdominal & Pelvic Infections

• Complicated intra-abdominal infections (e.g., peritonitis, biliary tract infections, intra-abdominal abscesses), mandatory in combination with an agent active against anaerobic pathogens (e.g., metronidazole).

6. Severe Gastrointestinal Infections

• Severe enteric fevers (Typhoid/Paratyphoid fever caused by Salmonella enterica serovars, accounting for regional fluoroquinolone resistance/elevated MICs).
• Severe shigellosis or empirical treatment of severe travelers' diarrhea with systemic toxicity.

7. Severe Skin and Soft Tissue Infections

• Deep tissue infections, necrotizing infections, diabetic foot infections, and decubitus ulcers caused by susceptible Gram-negative bacteria (co-administered with appropriate Gram-positive and anaerobic antimicrobial agents).

8. Anthrax (Post-Exposure Prophylaxis and Curative Treatment)

• Prophylaxis and treatment of inhalational anthrax following suspected or confirmed exposure to airborne spores of Bacillus anthracis.

9. Prophylaxis of Invasive Meningococcal Disease

• Single-dose chemoprophks for close contacts of patients with invasive Neisseria meningitidis infection (note: 500 mg is the standard single dose; the 750 mg strength may be used only if alternative strengths are unavailable, and local ciprofloxacin susceptibility of circulating meningococcal strains should be verified).

10. Neutropenic Patients with Fever

• Ciprofloxacin may be used, in combination with other appropriate antibacterial agents, in the management of neutropenic patients with fever suspected to be due to bacterial infection, in line with local protocols.

Regulatory Restrictions (EMA / FDA / MHRA Considerations)

Following the EMA's EU-wide review finalized in November 2018 (legally binding European Commission decision of March 2019), the EMA's 2023 Direct Healthcare Professional Communication, and the MHRA Drug Safety Update of January 2024, systemic fluoroquinolones must only be prescribed when other antibiotics that are commonly recommended for the infection are inappropriate. Fluoroquinolones must not be prescribed for:

• Infections that might resolve without treatment or are not severe (such as throat infections).
• Non-bacterial infections (e.g., non-bacterial chronic prostatitis) or viral infections.
• Prophylaxis of travelers' diarrhea or of recurrent lower urinary tract infections (infections confined to the bladder).
• Mild or moderate bacterial infections — including uncomplicated cystitis, acute bronchitis, acute uncomplicated sinusitis, and mild pharyngitis/tonsillitis — unless other antibacterial medicines commonly recommended for these infections cannot be used.

12. Administration

General Principles

Ciprobay® 750 mg tablets must be swallowed whole with an adequate volume of liquid (e.g., a full glass of water [250 mL]). They must not be chewed, crushed, split, or dissolved, as doing so damages the film coating, exposes the patient to an intensely bitter taste, and disrupts standard drug transit.

Patients must remain well-hydrated throughout therapy to maintain a dilute urine and prevent the precipitation of ciprofloxacin crystals (crystalluria) in alkaline conditions.

Recommended Adult Posology (Normal Renal Function: CrCl > 60 mL/min)

Clinical Indication	Dose & Frequency	Usual Duration
Severe / Complicated Lower Respiratory Tract Infections (or CF exacerbations)	750 mg every 12 hours (twice daily)	7 to 14 days (up to 21 days in CF)
Malignant External Otitis	750 mg every 12 hours (twice daily)	28 days up to 3 months
Chronic Suppurative Otitis Media	750 mg every 12 hours (twice daily)	7 to 14 days
Complicated Pyelonephritis (severe/pseudomonal)	750 mg every 12 hours (twice daily)	10 to 14 days (up to 21 days if abscess present)
Chronic Bacterial Prostatitis	750 mg every 12 hours (twice daily)	4 to 6 weeks
Complicated Bone and Joint Infections (Osteomyelitis)	750 mg every 12 hours (twice daily)	4 to 12 weeks (max 3 months)
Severe Intra-Abdominal Infections (+ Metronidazole)	750 mg every 12 hours (twice daily)	5 to 14 days
Severe Skin & Soft Tissue Infections (Gram-negative)	750 mg every 12 hours (twice daily)	7 to 14 days
Inhalational Anthrax (post-exposure prophylaxis / curative treatment)	500 mg every 12 hours	60 days from confirmation of exposure

Clinical Note: For inhalational anthrax, the officially approved oral adult dose per the EMA SmPC and the US FDA label is 500 mg twice daily for 60 days; the 750 mg strength is reserved for the severe/deep-seated indications listed above.

Renal Impairment Dosage Adjustments

Because ciprofloxacin is eliminated primarily via renal excretion, dosage adjustments are required based on creatinine clearance (CrCl):

Creatinine Clearance (mL/min/1.73 m²)	Serum Creatinine (µmol/L)	Recommended Oral Dosing Regimen
> 60	< 124	Standard dosing (500–750 mg every 12 hours)
30 – 60	124 – 168	250 to 500 mg every 12 hours (Note: The 750 mg tablet is generally too high; switch to lower strength tablets).
≤ 30	≥ 169	250 to 500 mg every 24 hours
Hemodialysis Patients	> 169	250 to 500 mg every 24 hours (administered after the hemodialysis session)
Peritoneal Dialysis	> 169	250 to 500 mg every 24 hours

Clinical Note regarding 750 mg strength in renal impairment: Because the 750 mg tablet is film-coated and not scored for titration, patients with moderate to severe renal impairment (CrCl < 60 mL/min) should be switched to commercially available 250 mg or 500 mg film-coated formulations to achieve precise dosage reductions.

Hepatic Impairment

No dose adjustment is required in patients with isolated hepatic impairment, provided renal function is preserved.

13. Method of Preparation

• Preparation Requirements: Not applicable. Ciprobay® 750 mg is a solid oral finished pharmaceutical product ready for direct administration.
• Handling & Crushing: The tablets must not be crushed or mixed with food/liquids. Crushing destroys the protective film coat, impairs swallowing tolerance due to extreme chemical bitterness, and poses potential occupational exposure risks. If a patient is unable to swallow solid tablets or is receiving enteral tube feedings, an intravenous formulation or an approved oral suspension should be utilized.

14. Contraindications

1. Hypersensitivity: Known hypersensitivity to ciprofloxacin, other members of the quinolone/fluoroquinolone class (e.g., levofloxacin, moxifloxacin, norfloxacin, ofloxacin), or to any of the inactive excipients listed in Section 20.
2. Concomitant Administration with Tizanidine: Co-administration is strictly contraindicated. Potent inhibition of CYP1A2 by ciprofloxacin causes a 7- to 10-fold increase in tizanidine exposure, resulting in life-threatening hypotension, severe bradycardia, profound sedation, and psychomotor collapse.
3. Concomitant Administration with Agomelatine: Contraindicated in many jurisdictions due to substantial increases in agomelatine plasma concentrations, which heighten the risk of severe hepatotoxicity.
4. History of Fluoroquinolone-Induced Serious Adverse Reactions: Use should generally be avoided — and a history of fluoroquinolone-associated tendinitis/tendon rupture is a contraindication — in patients who have previously experienced serious adverse reactions with a quinolone or fluoroquinolone antibiotic.

15. Warnings & Precautions

1. Disabling, Long-Lasting, Potentially Irreversible Adverse Reactions (Boxed / Class Warning)

Fluoroquinolones are associated with disabling, long-lasting, and potentially permanent multi-system adverse drug reactions, which may occur together in the same patient. These commonly involve:

• Musculoskeletal system (tendinitis, tendon rupture, arthralgia, myalgia).
• Peripheral nervous system (peripheral neuropathy, polyneuropathy, dysesthesias).
• Central nervous system and senses (psychosis, severe depression, sleep disorders, encephalopathy, impaired hearing, vision, taste and smell).
  At the first sign of any such symptom, ciprofloxacin must be discontinued immediately and the patient advised to contact the prescriber. In line with the MHRA Drug Safety Update (January 2024) and the EMA's post-referral measures, systemic fluoroquinolones must only be prescribed when other commonly recommended antibiotics are inappropriate.

2. Tendinitis and Tendon Rupture

• Risk is elevated in all age groups, but amplified in elderly patients (> 60 years), patients with chronic renal disease, solid organ transplant recipients, and those receiving concomitant systemic corticosteroids (combined use with corticosteroids should be avoided).
• Rupture of the Achilles tendon (often bilateral) may occur within 48 hours of treatment initiation, or up to several months post-cessation.
• Management: At the earliest emergence of tendon pain, erythema, or edema, ciprofloxacin must be halted immediately. The affected extremity must be strictly immobilized and off-loaded, and high-impact physical exertion prohibited.

3. Aortic Aneurysm and Aortic Dissection / Heart Valve Regurgitation

• Epidemiological studies indicate an increased risk of aortic aneurysm, aortic dissection, and aortic/mitral valve regurgitation within two months following fluoroquinolone therapy.
• The proposed mechanism involves degradation of structural collagen and elastin fibrils mediated by matrix metalloproteinases (MMPs).
• Precautions: Use only after careful benefit-risk evaluation in patients with pre-existing aneurysm, vascular connective tissue diseases (e.g., Marfan syndrome, vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome, Turner syndrome), systemic atherosclerosis, severe hypertension, giant cell arteritis, or pre-existing heart valve disease.
• Patients must be instructed to seek immediate emergency medical care if they experience sudden-onset severe chest, back, or abdominal pain, new-onset dyspnea, or peripheral edema.

4. Peripheral Neuropathy

• Cases of sensory or sensorimotor axonal polyneuropathy resulting in paresthesias, hypoesthesias, dysesthesias, burning sensations, or motor weakness have been documented.
• Ciprofloxacin must be discontinued immediately upon the emergence of neuropathic signs to prevent progression to permanent neurological deficit.

5. Central Nervous System (CNS) Toxicities & Psychiatric Disorders

• Fluoroquinolones lower seizure thresholds through competitive antagonism of central gamma-aminobutyric acid (GABA-A) receptors and activation of NMDA receptors. Caution is required in patients with known seizure disorders, structural cerebrovascular lesions, or cerebral trauma.
• Psychiatric reactions may manifest rapidly after the first dose, including acute anxiety, agitation, delirium, hallucinations, paranoia, depression, toxic confusional states, and suicidal ideation/behavior. Therapy must be discontinued if psychiatric symptoms arise.

6. Cardiac Electrophysiological Disturbances (QTc Prolongation)

• Fluoroquinolones block the rapid delayed rectifier potassium current (IKr), prolonging cardiac repolarization and QTc intervals, predisposing patients to ventricular arrhythmias and Torsades de Pointes.
• Avoid in patients with congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, decompensated heart failure, recent myocardial infarction, and in those taking concurrent Class IA or Class III antiarrhythmic agents or other QTc-prolonging drugs.

7. Severe Dysglycemia (Hypoglycemia / Hyperglycemia)

• Fluoroquinolones alter pancreatic beta-cell potassium-ATP channels, stimulating insulin secretion. Severe, life-threatening symptomatic hypoglycemia (including hypoglycemic coma) has been reported, predominantly in elderly diabetic patients receiving oral sulfonylureas (e.g., glibenclamide/glyburide) or exogenous insulin.
• Hyperglycemia may also occur. Intensive capillary blood glucose monitoring is mandatory in diabetic patients.

8. Clostridioides difficile-Associated Disease (CDAD)

• Ranging in severity from mild watery diarrhea to fulminant, fatal pseudomembranous colitis or toxic megacolon.
• If CDAD is suspected or confirmed, ciprofloxacin must be discontinued immediately. Fluid and electrolyte replacement should be initiated alongside targeted antibacterial therapy against C. difficile (oral vancomycin or fidaxomicin). Peristalsis-inhibiting anti-motility agents (e.g., loperamide) are contraindicated.

9. Severe Hepatotoxicity & Hepatic Necrosis

• Cases of acute hepatic necrosis, cholestatic hepatitis, and fatal liver failure have been reported.
• Patients must immediately stop medication and seek medical review if they develop anorexia, jaundice, scleral icterus, dark (tea-colored) urine, pruritus, or right upper quadrant tenderness.

10. Photosensitivity & Phototoxicity

• Exposure to direct sunlight, ultraviolet (UV) lamps, or tanning beds can precipitate moderate to severe erythema, blistering, and chemical dermatitis.
• Patients must avoid excessive UV light exposure and wear broad-spectrum sunscreens and protective clothing during therapy and for 48 hours following cessation.

11. Crystalluria & Renal Impairment

• Under neutral or alkaline urinary conditions (pH > 7.0), ciprofloxacin solubility declines sharply, which can result in the formation of needle-shaped ciprofloxacin crystals in the renal collecting system and tubules, causing tubulointerstitial nephritis or obstructive acute kidney injury.
• Maintain vigorous urinary output and avoid concurrent administration of urine alkalinizers (e.g., sodium bicarbonate, potassium citrate, carbonic anhydrase inhibitors).

12. Myasthenia Gravis Exacerbation

• Fluoroquinolones possess neuromuscular blocking activity and can trigger acute, life-threatening exacerbations of skeletal and respiratory muscle weakness in patients with myasthenia gravis. Fluoroquinolones should be avoided in this patient group (this risk is included in the US FDA boxed warning).

13. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

• Patients with latent or diagnosed G6PD deficiency exposed to ciprofloxacin are susceptible to acute hemolytic crises. Use only if clinical necessity strictly outweighs potential risks; monitor closely for hematocrit drops and hemoglobinuria.

16. Drug Interactions

Effect of Other Drugs on Ciprofloxacin

• Polyvalent Cation-Containing Preparations (Chelation):
  • Simultaneous oral administration of ciprofloxacin with products containing multivalent cations (calcium, magnesium, aluminum, iron, zinc, bismuth subsalicylate), buffered formulations (e.g., didanosine chewable tablets), sucralfate, or polymeric phosphate binders (sevelamer, lanthanum carbonate) causes rapid formation of insoluble chelate complexes, reducing oral ciprofloxacin bioavailability by 50% to 90%.
  • Timing Rule: Administer ciprofloxacin at least 1 to 2 hours before or at least 4 hours after taking multivalent cation supplements, antacids, or mineral-fortified products.
• Dairy Products & Calcium-Fortified Beverages:
  • When consumed alone outside of meals (e.g., drinking a glass of milk, yogurt, or calcium-fortified juice simultaneously with the tablet), absorption is reduced. Ciprofloxacin may, however, be taken with normal meals containing dairy components.
• Probenecid:
  • Inhibits renal tubular secretion of ciprofloxacin, increasing peak serum concentrations (Cmax) and AUC by approximately 50%, prolonging elimination half-life.
• Omeprazole / Proton Pump Inhibitors / H2 Blockers:
  • Concomitant omeprazole causes a minor reduction in ciprofloxacin bioavailability (Cmax and AUC decrease by 10–20%), but this is rarely of clinical significance.

Effect of Ciprofloxacin on Other Drugs (CYP1A2 Inhibition & Transporter Modulation)

• Tizanidine (CONTRAINDICATED):
  • Ciprofloxacin profoundly inhibits tizanidine metabolism via CYP1A2, increasing tizanidine Cmax up to 7-fold and AUC up to 10-fold. This causes severe, refractory hypotension, profound bradycardia, and excessive somnolence.
• Agomelatine (CONTRAINDICATED / AVOID):
  • Substantial elevations in agomelatine concentrations, increasing the risk of serious hepatotoxicity.
• Theophylline / Aminophylline:
  • Ciprofloxacin increases theophylline plasma concentrations by 30% to 100%, narrowing its therapeutic index and risking life-threatening theophylline toxicity (intractable nausea, cardiac tachyarrhythmias, status epilepticus). If co-administration cannot be avoided, reduce theophylline dosage by approximately 50% and perform therapeutic drug monitoring (TDM).
• Oral Anticoagulants (Vitamin K Antagonists - Warfarin, Acenocoumarol):
  • Augmentation of anticoagulant action via alteration of intestinal gut flora synthesizing vitamin K and potential metabolic interference. Frequent monitoring of International Normalized Ratio (INR) / Prothrombin Time is mandatory.
• Oral Hypoglycemic Agents (Sulfonylureas - Glibenclamide, Glimepiride):
  • Concomitant administration potentiates sulfonylurea action, precipitating severe hypoglycemia. Intensive capillary blood glucose monitoring is required.
• Methotrexate:
  • Ciprofloxacin inhibits the renal tubular transport of methotrexate, potentially raising systemic methotrexate levels and inducing severe bone marrow suppression, nephrotoxicity, and mucositis. Concomitant use is not recommended.
• Clozapine & Olanzapine:
  • Serum concentrations of these antipsychotics are increased due to CYP1A2 inhibition, raising the risk of sedation, anticholinergic toxicity, and seizures. Clinical monitoring and dosage reductions are advised.
• Duloxetine:
  • Co-administration with strong CYP1A2 inhibitors increases duloxetine AUC and Cmax significantly. Avoid concomitant use; if unavoidable, monitor closely for serotonin syndrome and adverse effects.
• Ropinirole:
  • Ropinirole Cmax and AUC increase by 60% and 84%, respectively. Monitor for dopaminergic adverse effects (dyskinesias, orthostatic hypotension) and adjust dose as necessary.
• Sildenafil:
  • Co-administration increases sildenafil exposure approximately two-fold (Cmax and AUC). Caution is advised, with consideration of a reduced starting dose of sildenafil.
• Zolpidem:
  • Concurrent administration may increase zolpidem plasma levels. Co-administration is not recommended.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):
  • Concomitant high-dose NSAID therapy (e.g., fenbufen, ibuprofen, naproxen) with fluoroquinolones increases the risk of CNS excitation, lowering the seizure threshold and precipitating convulsions.
• Cyclosporine:
  • A transient rise in serum creatinine concentrations has been observed when ciprofloxacin and cyclosporine are co-administered. Renal function tests (twice weekly) should be instituted.
• QTc-Prolonging Medications:
  • Concomitant use with Class IA antiarrhythmics (quinidine, procainamide, disopyramide), Class III antiarrhythmics (amiodarone, sotalol), tricyclic antidepressants, macrolides, or antipsychotics increases the risk of QTc prolongation and ventricular dysrhythmias.

17. Side Effects

Adverse drug reactions (ADRs) are categorized by MedDRA System Organ Class and standardized frequency definitions:

• Common: ≥ 1/100 to < 1/10
• Uncommon: ≥ 1/1,000 to < 1/100
• Rare: ≥ 1/10,000 to < 1/1,000
• Very Rare: < 1/10,000
• Frequency Not Known: (Cannot be estimated from available post-marketing surveillance data)

SYSTEM ORGAN CLASS	FREQUENCY	ADVERSE DRUG REACTION
Infections & Infestations	Uncommon:	Mycotic superinfections, Candida vulvitis
	Rare:	Clostridioides difficile colitis (pseudomembranous)
Blood & Lymphatic System Disorders	Uncommon:	Eosinophilia
	Rare:	Leukopenia, anemia, neutropenia, leukocytosis, thrombocytopenia, thrombocythemia
	Very Rare:	Hemolytic anemia, agranulocytosis, pancytopenia, bone marrow depression (life-threatening)
Immune System Disorders	Uncommon:	Allergic reaction, allergic edema / angioedema
	Rare:	Anaphylactic reaction, anaphylactic shock, serum sickness-like reaction
Metabolism & Nutrition Disorders	Uncommon:	Decreased appetite, anorexia
	Rare:	Hyperglycemia, severe hypoglycemia, hypoglycemic coma
Psychiatric Disorders	Uncommon:	Psychomotor hyperactivity, agitation
	Rare:	Confusional states, disorientation, anxiety, abnormal dreams, depression, hallucinations
	Very Rare:	Psychotic reactions, suicidal ideation/behavior
Nervous System Disorders	Uncommon:	Headache, dizziness, sleep disorders, dysgeusia
	Rare:	Paresthesias, dysesthesias, hypoesthesia, tremor, seizures (including status epilepticus), vertigo
	Very Rare:	Migraine, coordination disturbance, anosmia, intracranial hypertension (pseudotumor cerebri)
	Not Known:	Peripheral neuropathy, polyneuropathy
Eye & Ear Disorders	Uncommon:	Visual disturbances (diplopia, chromatopsia)
	Rare:	Tinnitus, transient hearing impairment / hypoacusis
Cardiac & Vascular Disorders	Rare:	Tachycardia, vasodilatation, syncope, hypotension
	Very Rare:	Leukocytoclastic vasculitis
	Not Known:	QTc prolongation, Torsades de Pointes, ventricular arrhythmia, aortic aneurysm/dissection
Respiratory System	Rare:	Dyspnea (including bronchospasm)
Gastrointestinal Disorders	Common:	Nausea, diarrhea
	Uncommon:	Vomiting, abdominal pain, dyspepsia, flatulence
	Very Rare:	Pancreatitis
Hepatobiliary Disorders	Uncommon:	Elevated transaminases (ALT, AST), elevated bilirubin
	Rare:	Hepatic impairment, cholestatic jaundice, hepatitis
	Very Rare:	Hepatic necrosis (progressing to liver failure)
Skin & Subcutaneous Tissues	Common:	Rash
	Uncommon:	Pruritus, urticaria
	Rare:	Photosensitivity reactions, phototoxicity
	Very Rare:	Petechiae, erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)
	Not Known:	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), AGEP
Musculoskeletal & Connective Tissue	Uncommon:	Arthralgia, joint swelling
	Rare:	Myalgia, arthritis, muscle cramps
	Very Rare:	Tendinitis, tendon rupture (Achilles tendon), exacerbation of myasthenia gravis symptoms
	Not Known:	Rhabdomyolysis
Renal & Urinary System	Uncommon:	Renal impairment
	Rare:	Tubulointerstitial nephritis, acute renal failure, crystalluria, hematuria
General & Administration Site Conditions	Uncommon:	Asthenia, fever, injection-site reactions (IV)
	Rare:	Edema, hyperhidrosis
Investigations	Uncommon:	Elevated serum alkaline phosphatase
	Rare:	Elevated amylase, elevated INR (with VKA)

18. Use in Special Populations

Pregnancy

• Safety Category: US FDA Category C (historically categorized; the FDA has since replaced letter categories with narrative labeling, but no new reassuring signal has emerged).
• Clinical Evidence: Data on exposure during human pregnancy (including observational registries) do not indicate overt teratogenic or feto/neonatal toxicities.
• Preclinical Risk: Juvenile animal studies consistently establish that fluoroquinolones induce degenerative arthropathy and cartilage lesions in weight-bearing joints of immature organisms.
• Recommendation: As a precautionary measure, ciprofloxacin is contraindicated or not recommended during pregnancy unless the clinical situation represents an immediate, life-threatening maternal condition where safer alternative antimicrobials cannot be used (e.g., inhalational anthrax).

Lactation & Breastfeeding

• Distribution in Milk: Ciprofloxacin is actively excreted into human breast milk. Relative infant doses of approximately 2% to 5% have been documented.
• Risks: Potential risks to the nursing infant include alterations of the intestinal microflora, candidiasis, diarrhea, and theoretical risks of articular cartilage toxicity.
• Recommendation: Ciprofloxacin is not recommended during breastfeeding. A decision must be made whether to discontinue nursing or refrain from initiating ciprofloxacin, balancing the importance of therapy to the mother against the developmental and health benefits of breastfeeding.

Pediatric Population (< 18 Years of Age)

• Ciprofloxacin causes arthropathy in the large weight-bearing joints of juvenile animals.
• Approved Narrow Indications:
  • Bronchopulmonary exacerbations in cystic fibrosis patients aged 5 to 17 years infected with P. aeruginosa.
  • Complicated urinary tract infections and pyelonephritis (aged 1 to 17 years) refractory to alternative first-line agents.
  • Inhalational anthrax (post-exposure prophylaxis and definitive treatment).
• Clinical Note: The 750 mg solid tablet cannot provide accurate weight-based pediatric dosing (which requires 10 to 20 mg/kg/dose) and must not be used in children unless the calculated dose matches the exact tablet strength. Alternative oral suspensions or lower strengths must be selected.

Geriatric Patients

• Elderly patients are at an elevated risk of severe adverse events:
  • Tendinitis and tendon rupture (amplified by age-related collagen changes and corticosteroid use).
  • Prolongation of the QTc interval and fatal dysrhythmias.
  • Rapid decline into severe, symptomatic hypoglycemia when on sulfonylurea or insulin therapy.
  • Aortic aneurysm rupture and dissection.
• Because elderly patients frequently present with occult age-related reductions in renal function, dosing must be titrated based on calculated creatinine clearance rather than chronological age.

Renal Impairment

• Ciprofloxacin is substantially cleared via renal excretion. Declines in glomerular filtration rate produce proportionate decreases in renal clearance and elevations in systemic drug exposure (AUC).
• Guideline: Dosage reductions are mandatory when CrCl < 60 mL/min (see Section 12). Because 750 mg tablets are unscored, patients requiring dose decrements to 250 mg or 500 mg must be provided an alternative tablet strength.

Hepatic Impairment

• Pharmacokinetic profile is generally preserved in patients with isolated hepatic dysfunction. No routine dose reduction is necessary, though periodic monitoring of hepatic transaminases is recommended.

19. Storage Conditions

• Temperature: Store at controlled room temperature, not exceeding 30°C (86°F).
• Moisture & Light: Store in the original commercial packaging (aluminum/PVDC blisters) to protect from ambient humidity and direct sunlight.
• Safety Precautions: Keep strictly out of the reach and sight of children.
• Shelf Life: 36 months (3 years) from the date of manufacture when stored in intact original packaging. Do not use beyond the expiration date stamped on the carton and blister foil.

20. Additional Sections

Inactive Excipients

• Tablet Core:
  • Microcrystalline cellulose
  • Crospovidone (Type A)
  • Maize starch
  • Magnesium stearate
  • Silica colloidal anhydrous
• Film Coating:
  • Hypromellose (hydroxypropyl methylcellulose)
  • Macrogol 4000 (polyethylene glycol)
  • Titanium dioxide (E171)
• Allergen Note: The formulation is free from gluten and lactose.

Management of Overdose

• Clinical Presentation: Acute overdose (ranging from 12 g to 16 g) may produce severe dizziness, tremors, headaches, extreme lethargy, generalized tonic-clonic seizures, visual and auditory hallucinations, confusional delirium, abdominal discomfort, elevated serum creatinine, acute tubular necrosis, and massive crystalluria with macroscopic hematuria. Marked QTc prolongation can occur.
• Emergency Management:
  1. No specific chemical antidote exists.
  2. Maintain a patent airway, monitor continuous 12-lead electrocardiography (ECG) for QTc interval changes, and manage seizures with intravenous benzodiazepines.
  3. Evacuate stomach contents via gastric lavage or induce medicinal adsorption via oral administration of activated charcoal (within 1 to 2 hours of ingestion).
  4. Administer intravenous crystalloid fluids to maintain high urine output and dilute urinary drug concentrations.
  5. Check urinary pH; if urinary alkalinization is present, urine acidification may be considered (with caution) to avert nephrotoxic ciprofloxacin crystallization.
  6. Dialysis Clearance: Only a minor fraction of ciprofloxacin (< 10%) is eliminated by hemodialysis or peritoneal dialysis; therefore, dialysis is ineffective for rapid drug clearance.

Antimicrobial Stewardship & Resistance Prevention

• Indiscriminate use of fluoroquinolones drives community and nosocomial selection pressure for multi-drug-resistant (MDR) Enterobacterales (producing Extended-Spectrum Beta-Lactamases [ESBLs] or carbapenemases) and fluoroquinolone-resistant P. aeruginosa.
• Prescribing must be guided by microbiological culture and susceptibility testing (EUCAST methodology). Empirical use of 750 mg twice daily should be reserved for high-acuity infections with high pre-test probability of resistant Gram-negative involvement.
• Fluoroquinolones are classified in the WHO AWaRe "Watch" group and are a priority target of national antimicrobial stewardship programmes; a 2023 EMA-commissioned drug utilization study (EUPAS37856) found that fluoroquinolones continued to be prescribed outside their restricted uses, prompting renewed regulator reminders — reinforcing the need for prescriber-level audit and feedback.

21. Frequently Asked Questions (FAQ)

Q1: Why is Ciprobay prescribed at a high 750 mg dose instead of the standard 500 mg dose?

The 750 mg strength is reserved for deep-seated, severe, or difficult-to-treat infections caused by organisms with higher minimum inhibitory concentrations (MICs), such as Pseudomonas aeruginosa or bacteria causing chronic bone infections (osteomyelitis) and malignant external otitis. The higher dose achieves peak concentrations and AUC exposures necessary to eradicate these pathogens and suppress the emergence of resistant bacterial subpopulations.

Q2: Can Ciprobay 750 mg tablets be cut in half or crushed to make them easier to swallow?

No. Ciprobay 750 mg tablets are film-coated and must be swallowed whole with a full glass of water. Crushing or splitting them destroys the protective outer coating, exposes the oral cavity and esophagus to an unpalatable, bitter chemical compound, and can cause local mucosal irritation. If you have difficulty swallowing or require a reduced dose due to kidney disease, your physician should prescribe a lower commercial strength (such as 250 mg or 500 mg) or an alternative liquid/intravenous formulation.

Q3: Can I take Ciprobay with milk, yogurt, or calcium-enriched juices?

No. You should not take Ciprobay with dairy products alone or mineral-fortified beverages. Calcium binds directly to ciprofloxacin in the digestive tract, forming an insoluble complex that prevents the antibiotic from being absorbed into your bloodstream, leading to treatment failure. However, taking Ciprobay with a full, normal meal that contains modest amounts of dairy components is acceptable because food proteins and fluids minimize this interaction.

Q4: What should I do if I experience sudden tendon pain or swelling in the back of my ankle while taking Ciprobay?

Stop taking the medication immediately, avoid walking or putting weight on the affected limb, and contact your treating physician or seek emergency medical care. Tendon pain, swelling, and inflammation are early signs of tendinitis or an impending tendon rupture (most commonly affecting the Achilles tendon). Continuing to take the medication or exercising through the pain significantly increases the risk of a complete tear, which may require surgical repair and cause long-term disability.

Q5: Are there any specific warning signs that require immediate emergency room attention?

Yes. Seek emergency medical attention immediately if you develop:

• Sudden, severe, tearing pain in your chest, back, or abdomen (signs of an aortic aneurysm or dissection).
• Shortness of breath or rapid swelling of your ankles/legs.
• Severe burning, numbness, tingling, or weakness in your hands, arms, feet, or legs.
• Rapid changes in mood, severe confusion, hallucinations, or thoughts of self-harm.
• Signs of a severe allergic reaction (swelling of your face, lips, tongue, or throat, or difficulty breathing).
• Profuse, watery, or bloody diarrhea accompanied by abdominal cramps and fever.

22. References

1. European Medicines Agency (EMA): Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Article 31 referral (EMEA/H/A-31/1452); PRAC recommendations 4 October 2018; CHMP opinion 15 November 2018; legally binding European Commission decision 11 March 2019 (EMA/175398/2019).
2. European Medicines Agency (EMA): Direct Healthcare Professional Communication and press materials (May 2023) — reminder of the restricted use of systemic and inhaled fluoroquinolones, following the EMA-commissioned drug utilization study (EUPAS37856) showing continued prescribing outside recommended uses.
3. UK Medicines and Healthcare products Regulatory Agency (MHRA): Drug Safety Update, January 2024 — "Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate."
4. European Medicines Agency (EMA): Summary of Product Characteristics (SmPC) – Ciprobay (Ciprofloxacin) 250 mg, 500 mg, and 750 mg film-coated tablets. Bayer AG, Leverkusen, Germany.
5. US Food and Drug Administration (FDA): FDA Drug Safety Communication (26 July 2016): FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling and potentially irreversible side effects.
6. US Food and Drug Administration (FDA): FDA Drug Safety Communication (10 July 2018): FDA reinforces safety information about serious low blood sugar levels (hypoglycemia) and mental health side effects with fluoroquinolone antibiotics; requires label changes.
7. US Food and Drug Administration (FDA): FDA Drug Safety Communication (20 December 2018): FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients.
8. US Food and Drug Administration (FDA): Cipro® (ciprofloxacin hydrochloride) Tablets Prescribing Information. Bayer HealthCare Pharmaceuticals Inc.
9. The European Committee on Antimicrobial Susceptibility Testing (EUCAST): Breakpoint tables for interpretation of MICs and zone diameters. Version 16.0, valid from 1 January 2026 (clinical breakpoints for fluoroquinolones).
10. Egyptian Drug Authority (EDA) & Hikma Pharmaceuticals: Authorized Technical Package Insert & Leaflet: Ciprobay (Ciprofloxacin Hydrochloride) 750 mg Film-Coated Tablets. Hikma Pharma S.A.E., 6th of October City, Egypt, under license from Bayer Schering Pharma AG.
11. Infectious Diseases Society of America (IDSA): Clinical Practice Guidelines for the Management of Complicated Urinary Tract Infections and Catheter-Associated Urinary Tract Infections.
12. Hooper DC, Rubinstein E (Eds.): Quinolone Antimicrobial Agents, 3rd Edition, American Society for Microbiology (ASM) Press — Clinical pharmacokinetics of ciprofloxacin: absorption, distribution, metabolism and elimination profile.
13. World Health Organization (WHO): AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use. Fluoroquinolones classified under the "Watch" group due to higher resistance potential.